Press
back to blog

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Press
This is some text inside of a div block.
April 5, 2024

Media Contacts

Related announcements

View All
View All
December 11, 2024

Iambic Therapeutics Announces Appointment of Peter Olson, Ph.D., as Chief Scientific Officer

Read more
December 11, 2024

Iambic Therapeutics Announces Appointment of Peter Olson, Ph.D., as Chief Scientific Officer

Read more
November 1, 2024

Previewing NeuralPLexer3: Towards fully AI-enabled Structure-Based Drug Discovery

Read more
November 1, 2024

Previewing NeuralPLexer3: Towards fully AI-enabled Structure-Based Drug Discovery

Read more
October 29, 2024

Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery

Read more
October 29, 2024

Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery

Read more